595 related articles for article (PubMed ID: 26315756)
1. Highly active antiretroviral therapy and dyslipidemia in people living with HIV/AIDS in Fako Division, South West Region of Cameroon.
Nsagha DS; Weledji EP; Assob NJ; Njunda LA; Tanue EA; Kibu OD; Ayima CW; Ngowe MN
BMC Cardiovasc Disord; 2015 Aug; 15():95. PubMed ID: 26315756
[TBL] [Abstract][Full Text] [Related]
2. Antiretroviral treatment associated hyperglycemia and dyslipidemia among HIV infected patients at Burayu Health Center, Addis Ababa, Ethiopia: a cross-sectional comparative study.
Abebe M; Kinde S; Belay G; Gebreegziabxier A; Challa F; Gebeyehu T; Nigussie P; Tegbaru B
BMC Res Notes; 2014 Jun; 7():380. PubMed ID: 24950924
[TBL] [Abstract][Full Text] [Related]
3. The lipid profile of HIV-infected patients receiving antiretroviral therapy in a rural Cameroonian population.
Bekolo CE; Nguena MB; Ewane L; Bekoule PS; Kollo B
BMC Public Health; 2014 Mar; 14():236. PubMed ID: 24606888
[TBL] [Abstract][Full Text] [Related]
4. Changes in lipid profile over 24 months among adults on first-line highly active antiretroviral therapy in the home-based AIDS care program in rural Uganda.
Buchacz K; Weidle PJ; Moore D; Were W; Mermin J; Downing R; Kigozi A; Borkowf CB; Ndazima V; Brooks JT
J Acquir Immune Defic Syndr; 2008 Mar; 47(3):304-11. PubMed ID: 18398971
[TBL] [Abstract][Full Text] [Related]
5. Dyslipidemia and associated risk factors among HIV/AIDS patients on HAART in Asmara, Eritrea.
Achila OO; Abrhaley F; Kesete Y; Tesfaldet F; Alazar F; Fisshaye L; Gebremeskel L; Mehari R; Andemichael D
PLoS One; 2022; 17(7):e0270838. PubMed ID: 35776747
[TBL] [Abstract][Full Text] [Related]
6. HAART, DOTS and renal disease of patients co-infected with HIV/AIDS and TB in the South West Region of Cameroon.
Nsagha DS; Pokam BT; Assob JC; Njunda AL; Kibu OD; Tanue EA; Ayima CW; Weledji PE
BMC Public Health; 2015 Oct; 15():1040. PubMed ID: 26452646
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of dyslipidemia and dysglycaemia in HIV infected patients.
Manuthu EM; Joshi MD; Lule GN; Karari E
East Afr Med J; 2008 Jan; 85(1):10-7. PubMed ID: 18543521
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of dyslipidemia among human immunodeficiency virus infected Nigerians.
Muhammad S; Sani MU; Okeahialam BN
Ann Afr Med; 2013; 12(1):24-8. PubMed ID: 23480991
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of dyslipidemia among HIV-infected patients using first-line highly active antiretroviral therapy in Southern Ethiopia: a cross-sectional comparative group study.
Tadewos A; Addis Z; Ambachew H; Banerjee S
AIDS Res Ther; 2012 Oct; 9(1):31. PubMed ID: 23095661
[TBL] [Abstract][Full Text] [Related]
10. Dyslipidemia in AIDS patients on highly active antiretroviral therapy.
Nery MW; Martelli CM; Turchi MD
Braz J Infect Dis; 2011; 15(2):151-5. PubMed ID: 21503402
[TBL] [Abstract][Full Text] [Related]
11. First-line antiretroviral therapy and dyslipidemia in people living with HIV-1 in Cameroon: a cross-sectional study.
Pefura Yone EW; Betyoumin AF; Kengne AP; Kaze Folefack FJ; Ngogang J
AIDS Res Ther; 2011 Sep; 8():33. PubMed ID: 21943115
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of Hypertension in HIV/AIDS Patients on Highly Active Antiretroviral Therapy (HAART) Compared with HAART-Naïve Patients at the Limbe Regional Hospital, Cameroon.
Dimala CA; Atashili J; Mbuagbaw JC; Wilfred A; Monekosso GL
PLoS One; 2016; 11(2):e0148100. PubMed ID: 26862763
[TBL] [Abstract][Full Text] [Related]
13. Burden of metabolic syndrome among HIV-infected patients in Southern Ethiopia.
Tesfaye DY; Kinde S; Medhin G; Megerssa YC; Tadewos A; Tadesse E; Shimelis T
Diabetes Metab Syndr; 2014; 8(2):102-7. PubMed ID: 24907175
[TBL] [Abstract][Full Text] [Related]
14. Dietary intervention prevents dyslipidemia associated with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected individuals: a randomized trial.
Lazzaretti RK; Kuhmmer R; Sprinz E; Polanczyk CA; Ribeiro JP
J Am Coll Cardiol; 2012 Mar; 59(11):979-88. PubMed ID: 22402068
[TBL] [Abstract][Full Text] [Related]
15. The Effectiveness of a Bioactive Food Compound in the Lipid Control of Individuals with HIV/AIDS.
Dos Santos Ferreira R; de Cássia Avellaneda Guimarães R; Jardim Cury Pontes ER; Aragão do Nascimento V; Aiko Hiane P
Nutrients; 2016 Oct; 8(10):. PubMed ID: 27740592
[TBL] [Abstract][Full Text] [Related]
16. Serum Interleukin-6 and Weight Loss in Antiretroviral-naïve and Antiretroviral-treated Patients with HIV/AIDS: Relationships and Predictors.
Adedeji TA; Adedeji NO; Ajeigbe AK; Smith OS; Jeje OA; Fawale MB; Ajose AO; Adebisi SA; Akande AA; Okesina BA
Curr HIV Res; 2022; 20(6):441-456. PubMed ID: 36056868
[TBL] [Abstract][Full Text] [Related]
17. A Comparison of the Diabetes Risk Score in HIV/AIDS Patients on Highly Active Antiretroviral Therapy (HAART) and HAART-Naïve Patients at the Limbe Regional Hospital, Cameroon.
Dimala CA; Atashili J; Mbuagbaw JC; Wilfred A; Monekosso GL
PLoS One; 2016; 11(5):e0155560. PubMed ID: 27195956
[TBL] [Abstract][Full Text] [Related]
18. Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir.
Llibre JM; Domingo P; Palacios R; Santos J; Pérez-Elías MJ; Sánchez-de la Rosa R; Miralles C; Antela A; Moreno S;
AIDS; 2006 Jun; 20(10):1407-14. PubMed ID: 16791015
[TBL] [Abstract][Full Text] [Related]
19. [Lipodystrophy and echographic hepatic steatosis in HIV-positive patients under highly active antiretroviral therapy (HAART) in Yaounde (Cameroon)].
Ongolo-Zogo P; Nkodo Mbia N; Mvogo Minkala TL; Biwole Sida M; Kouanfack C; Nko Amvene S
Bull Soc Pathol Exot; 2012 Dec; 105(5):353-60. PubMed ID: 22886433
[TBL] [Abstract][Full Text] [Related]
20. Serum lipid profile in highly active antiretroviral therapy-naïve HIV-infected patients in Cameroon: a case-control study.
Nguemaïm NF; Mbuagbaw J; Nkoa T; Alemnji G; Této G; Fanhi TC; Asonganyi T; Samé-Ekobo A
HIV Med; 2010 Jul; 11(6):353-9. PubMed ID: 20345886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
